CO5021213A1 - INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8 - Google Patents

INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8

Info

Publication number
CO5021213A1
CO5021213A1 CO99038264A CO99038264A CO5021213A1 CO 5021213 A1 CO5021213 A1 CO 5021213A1 CO 99038264 A CO99038264 A CO 99038264A CO 99038264 A CO99038264 A CO 99038264A CO 5021213 A1 CO5021213 A1 CO 5021213A1
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
halogen
independently selected
group
Prior art date
Application number
CO99038264A
Other languages
English (en)
Inventor
James Francis Callahan
Fletcher Marie C Chabot
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5021213A1 publication Critical patent/CO5021213A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica, que comprende un compuesto defórmula I:en la cual :RA sustituye el anillo A 0-3 veces y se selecciona independientemente entre el grupo que consiste en : NO2 , halógeno, alquilo C1-6 , trifluorometilo, O-alquilo C1-6 y S-alquilo C1-6 ; yRB sustituye el anillo B O-3 veces y se selecciona independientemente entre el grupo que consiste en: halógeno, C(O)-alquilo C1-6 , alquilo C1-6 , O-alquilo C1-6 , S-alquilo C1-6 , CH2 -arilo y arilo; y sus sales, hidratos y solvatos farmacéuticamente aceptables.Un método para inhibir NF-kB, que comprende administrar a un paciente que lo necesita una cantidad eficaz de un compuesto de fórmula I:en la cual :RA sustituye el anillo A 0-3 veces y se selecciona independientemente entre el grupo que consiste en : NO2 , halógeno, alquilo C1-6 , trifluorometilo, O-alquilo C1-6 y S-alquilo C1-6 ; y RB sustituye el anillo B 0-3 veces y se selecciona independientemente entre el grupo que consiste en : halógeno, C(O)-alquilo C1-6 , alquilo C1-6 , O-alquilo C1-6 , S-alquilo C1-6 , CH2 -arilo y arilo; y sus sales, hidratos y solvatos farmacéuticamente aceptables.
CO99038264A 1998-06-19 1999-06-18 INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8 CO5021213A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8982798P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
CO5021213A1 true CO5021213A1 (es) 2001-03-27

Family

ID=22219773

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99038264A CO5021213A1 (es) 1998-06-19 1999-06-18 INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8

Country Status (21)

Country Link
US (3) US6492425B1 (es)
EP (1) EP1085848B1 (es)
JP (1) JP2002518307A (es)
KR (1) KR20010052991A (es)
CN (1) CN1311629A (es)
AR (1) AR019692A1 (es)
AT (1) ATE383769T1 (es)
AU (1) AU4690099A (es)
BR (1) BR9911152A (es)
CA (1) CA2335294A1 (es)
CO (1) CO5021213A1 (es)
CZ (1) CZ20004761A3 (es)
DE (1) DE69937997T2 (es)
ES (1) ES2299251T3 (es)
HU (1) HUP0102782A3 (es)
IL (1) IL140328A0 (es)
NO (1) NO20006451L (es)
PL (1) PL348969A1 (es)
TR (1) TR200003781T2 (es)
WO (1) WO1999065449A2 (es)
ZA (1) ZA200007447B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951551B9 (en) 1996-12-23 2012-12-26 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
FR2813315B1 (fr) * 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
AU2002222683B9 (en) * 2000-12-18 2021-12-23 Institute Of Medicinal Molecular Design, Inc Inflammatory cytokine release inhibitor
JP4599501B2 (ja) 2001-11-07 2010-12-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
TW200407112A (en) * 2002-06-05 2004-05-16 Inst Med Molecular Design Inc Immunity-related protein kinase inhibitors
JP4743382B2 (ja) * 2002-06-06 2011-08-10 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
JP4660674B2 (ja) * 2002-06-06 2011-03-30 株式会社医薬分子設計研究所 抗アレルギー薬
AU2003242098B2 (en) * 2002-06-10 2008-11-20 Institute Of Medicinal Molecular Design, Inc Inhibitors against activation of NFkappaB
JPWO2003103655A1 (ja) * 2002-06-10 2005-10-06 株式会社医薬分子設計研究所 癌治療剤
CA2488979A1 (en) * 2002-06-11 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of neurodegenerative diseases
US7324455B2 (en) 2003-03-14 2008-01-29 International Business Machines Corporation Transfer of error-analysis and statistical data in a fibre channel input/output system
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
US20050256132A1 (en) * 2003-04-30 2005-11-17 Wyeth Use of ER selective NF-kB inhibitors for the treatment of sepsis
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
TWI376370B (en) * 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
US7671058B2 (en) * 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
CA2703494A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of pai-1 production
US20110111070A1 (en) 2007-10-25 2011-05-12 Yung-Chi Cheng Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
WO2009089277A2 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
US20090264514A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2654428B1 (en) * 2010-12-22 2018-02-14 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
TWI492920B (zh) * 2012-04-18 2015-07-21 Nat Defense Medical Ct 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
US9562002B2 (en) 2013-01-15 2017-02-07 Board Of Regents, The University Of Texas System STAT3 inhibitor
CN114621346A (zh) 2013-08-21 2022-06-14 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
EP3126332A4 (en) * 2014-03-31 2017-09-06 The Trustees of Columbia University in the City of New York Histone acetyltransferase activators and uses thereof
ES2970434T3 (es) 2014-09-12 2024-05-28 Union Therapeutics As Uso antibacteriano de salicilanilidas halogenadas
CN105797154B (zh) * 2014-12-31 2020-03-10 中国科学院上海生命科学研究院 软骨干细胞的分离及其应用
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2017122209A2 (en) * 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
CN110650958A (zh) * 2017-03-21 2020-01-03 诺瓦莱德制药公司 用于磷酸二酯酶抑制及其相关病症的治疗剂
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN114727975A (zh) * 2019-11-18 2022-07-08 加利福尼亚大学董事会 双雄激素受体/akr1c3抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079177A (en) * 1963-06-11 1967-08-16 Stecker Internat S P A Improvements in pesticide composition for destroying internal worm parasites in animals
GB1079178A (en) * 1966-07-27 1967-08-16 Stecker Internat S P A Improvements in pesticide compositions for destroying internal worm parasites in animals
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4803279A (en) 1985-05-23 1989-02-07 Smithkline Beckman Corporation 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
AU8495091A (en) * 1990-08-21 1992-03-17 Upjohn Company, The Bisphosphonic acid derivatives as anti-arthritic agents
CA2102704A1 (en) * 1991-05-17 1992-11-18 John Stephen Haskill Inhibitor of nf-kb transcriptional activator and uses thereof
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
DE4200534A1 (de) * 1992-01-11 1993-07-15 Henkel Kgaa Neue n-benzyl-4-aminophenole und deren verwendung als entwicklerkomponente in oxidationshaarfaerbemitteln
ZA944191B (en) * 1993-06-15 1995-02-08 Univ Australian Synergistic anthelmintic compositions
WO1999007382A1 (en) * 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
AU4690099A (en) 2000-01-05
KR20010052991A (ko) 2001-06-25
US20030092771A1 (en) 2003-05-15
PL348969A1 (en) 2002-06-17
BR9911152A (pt) 2001-03-06
WO1999065449A8 (en) 2001-03-08
US6492425B1 (en) 2002-12-10
US20060035979A1 (en) 2006-02-16
CZ20004761A3 (cs) 2001-08-15
CN1311629A (zh) 2001-09-05
ES2299251T3 (es) 2008-05-16
TR200003781T2 (tr) 2001-07-23
HUP0102782A2 (hu) 2001-12-28
WO1999065449A3 (en) 2000-03-30
DE69937997D1 (es) 2008-03-06
ZA200007447B (en) 2002-02-13
JP2002518307A (ja) 2002-06-25
EP1085848B1 (en) 2008-01-16
NO20006451D0 (no) 2000-12-18
EP1085848A4 (en) 2004-09-08
NO20006451L (no) 2000-12-18
CA2335294A1 (en) 1999-12-23
ATE383769T1 (de) 2008-02-15
HUP0102782A3 (en) 2002-12-28
AR019692A1 (es) 2002-03-13
EP1085848A2 (en) 2001-03-28
WO1999065449A2 (en) 1999-12-23
IL140328A0 (en) 2002-02-10
DE69937997T2 (de) 2009-02-19

Similar Documents

Publication Publication Date Title
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2'.
DE69830504D1 (de) Antithrombotische mitteln
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
AR034556A1 (es) Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado
ATE306261T1 (de) Antithrombosemittel
KR950032258A (ko) 세포부착 저해제로서의 설페이트화 알파(α)-당지질 유도체
AR023289A1 (es) COMPUESTOS CON ACTIVIDAD INHIBIDORA DE ENDOPEPTIDASA NEUTRA (NEP), COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y PROCEDIMIENTO PARA SU PREPARACIoN.
CO5720995A2 (es) Compuesto novedoso
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
ES2081178T3 (es) Compuestos anti-tumorales que contienen anillos quinazolina y tetrazol.
AR006606A1 (es) Derivados de isatina como inhibidores de la acetilcolinesterasa y analgesicos, composicion farmaceutica, metodos de tratamaiento, usos yprocedimiento de dichos derivados.
AR008782A1 (es) Una composicion farmaceutica antitrombotica y antiaterogena, y sus usos
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
ES2179523T3 (es) Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados.
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
ES2036137B1 (es) Procedimiento para la preparacion de la nueva 1-(3-clorofenil)-4-hidroximetil-7,8-dimetoxi-5h-2,3-benzodiacepina y de sus sales de adicion acida.
KR960037677A (ko) 4-인돌릴피페라지닐 유도체
HUP0301010A2 (hu) A koleszteril-észter és a viaszészter szintézisét egyaránt gátló vegyületek faggyúmirigy-betegségek kezeléséhez és ezeket tartalmazó gyógyszerkészítmények
CO5280088A1 (es) Inhibidores de proteasa
BR0111767A (pt) Composições analgésicas e anti-inflamatórias contendo inibidores de cox-2, seu uso e método para potencializar um composto analgésico
AR004675A1 (es) Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas.